Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases

Exclusion Criteria

• •Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs on either:
• •* single TheraSphere administration; or
• •* cumulative delivery of radiation to the lungs greater than 50 Gy over multiple treatments.
• •Evidence of any detectable Tc-99m macroaggregated albumin deposition in the stomach or duodenum, after application of established angiographic techniques to stop such deposition.
• •Previous radiation therapy to the lungs and/or to the upper abdomen
• •Pregnancy
• •Symptomatic lung disease.
• •Significant extrahepatic disease representing an imminent life-threatening outcome.
• •Active uncontrolled infection
• •Any pre-treatment laboratory findings within 30 days of treatment demonstrating:
• •* Aspartate or alanine aminotransferase level greater than 5 times upper normal limit.
• •* Serum bilirubin greater than 2 mg/dl
• •* Infiltrative tumor on imaging
• •* Tumor volume greater than 70% of liver volume
• •* Tumor volume greater than 50% of liver volume and serum albumin level less than 3 mg/dL